Abstract:
Pesticidal 1,4-diaryl-2,3-difluoro-2-butene compounds of formula (I) wherein Ar is phenyl, 1- or 2-naphtyl or a 5- or 6-membered heteroaromatic ring all of which aromatic systems may be optionally substituted; is C2-C6-alkenyl, C4-C6-cycloalkenyl or C1-C2-alkoxy-C2-C6-alkyl; and Ar is phenoxyphenyl, phenyl, biphenyl, phenoxypyridyl, benzylpyridyl, benzylphenyl, benzoylphenyl, 1- or 2-naphthyl, or a 5 or 6-membered heteroaromatic ring all of which aromatic systems may be optionally substituted, intermediates and methods for the preparation of compounds of formula (I) and compositions and methods comprising the compounds and compositions for the control of insect and acarid pests.
Abstract:
This invention generally relates to nanocrystal compounds, and linker arm for nanocrystal compounds that attach the nanocrystals to the organic compounds. The nanocrystal compound comprises a nanocrystal, linker arm, and organic compound. Preferably, the organic compound is a biologically active compound that can provide a fluorescent sensor. Preferably, the linker arm is a polyether chain with an attachment point for the nanocrystal and an attachment point for the organic compound. Specifically, the nanocrystal is attached to the linker arm through a R group and the organic compound is attached to the linker arm through a R2 group.R is a bond or is selected from the group consisting of: SH, O(CH2(n)O)nSH, NH(CH2(n)O)nSH, NH(CH2(n)NH)SH, S(CH2(n)O)nSH, and S(CH2(n)S)SH. n is 1-10, with S being attached to the nanocrystal. R2 is a bond or selected from the group consisting of carbonyl, NH, S, CONH, COO, S, C1-10 alkyl, carbamate, and thiocarbamate.
Abstract:
A process for producing a sulfur compound bearing at least one thio group in the molecule by reacting a thiol compound with an organic compound bearing at least one functional group capable of reacting with a mercapto group to thereby form a thio group in the presence of a basic compound, characterized by adjusting the number of moles of water contained in the reaction system to at most 7.5 times the product of the number of moles of the reactant thiol compound and the number of mercapto groups existing in one molecule of the thiol compound.
Abstract:
The present invention relates to certain phenalkyloxy-phenyl derivatives of formula (I) and analogs, to a process for preparing such compounds, having the utility in clinical conditions associated with insulin resistance, to methods for their therapeutic use and to pharmaceutical compositions containing them.
Abstract:
The invention relates to a process for preparing a benzothiazolone compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof, wherein Ph represents a phenyl group, having pharmacological activity and to intermediates used in their preparation.
Abstract:
The invention relates to a method for producing derivatives of 4-alkylsulfinyl methylarylene methanols. Derivatives of 4-alkylsulfinyl methylarylene methanols are valuable monomers in the production of conjugated polymers, which are suitable for use as electroluminescent materials.
Abstract:
Substituted pyridines of formula (IA) are produced by reaction of suitably substituted pyridylaldehydes with Grignard or Witting reagents, and the resulting products are appropriately reduced. The pyridines of formula (IA) are suitable as active compounds in pharmaceutical products, particularly in pharmaceutical products for the inhibition of cholesterol ester transfer proteins. 3-Heteroalkyl-aryl-substituted pyridines of formula (IB) are produced from pyridines which are correspondingly protected at the hydroxy group and correspondingly substituted. The compounds of formula (IB) according to the invention are suitable as active compounds in pharmaceutical products, particularly pharmaceutical products for the treatment of hyperlipoproteinemia. Substituted pyridines and benzenes of formula (IC) are produced by procedures disclosed herein, and are useful as active ingredients in pharmaceutical products, particularly pharmaceutical products for inhibition of the glucagon receptor, leading to treatment of glucagon-mediated conditions such as diabetes.
Abstract:
Compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R1 is (a) hydrogen, (b) loweralkyl, (c) alkenyl, (d) alkoxy, (e) thioalkoxy, (f) halo, (g) haloalkyl, (h) aryl-L2-, and (i) heterocyclic-L2-; R2 is selected from (a) (Ia), (b) -C(O)NH-CH(R14)-C(O)OR15, (c) (Ib), (d) -C(O)NH-CH(R14)-C(O)NHSO2R16, (e) -C(O)NH-CH(R14)-tetrazolyl, (f) -C(O)NH-heterocyclic, and (g) -C(O)NH-CH(R14)-C(O)NR17R18; R3 is substituted or unsubstituted heterocyclic or aryl, substituted or unsubstituted cycloalkyl or cycloalkenyl, (Ic), and -P(W)R R ; R4 is hydrogen, lower alkyl, haloalkyl, halogen, aryl, arylakyl, heterocyclic, or (heterocyclic)alkyl; L1 is absent or is selected from (a) -L4-N(R5)-L5-, (b) -L4-O-L5-, (c) -L4-S(O)n-L5-, (d) -L4-L6-C(W)-N(R5)-L5-, (e) -L4-L6-S(O)m-N(R5)-L5-, (f) -L4-N(R5)-C(W)-L7-L5-, (g) -L4-N(R5)-S(O)p -L7-L5-, (h) optionally substituted alkylene, (i) optionally substituted alkenylene, (j) optionally substituted alkynylene, (k) a covalent bond, (l) (Id), and (m) (Ie) are inhibitors of protein isoprenyl transferases. Also disclosed are protein isoprenyl transferase inhibiting compositions and a method of inhibiting protein isoprenyl transferases.
Abstract translation:具有式(I)化合物或其药学上可接受的盐,其中R 1是(a)氢,(b)低级烷基,(c)烯基,(d)烷氧基,(e)硫代烷氧基,(f)卤素,(g)卤代烷基, (h)芳基-L2-和(i)杂环-L2-; R2选自(a)(Ia),(b)-C(O)NH-CH(R14)-C(O)OR15,(c)(Ib),(d)-C(O)NH-CH (R 14)-C(O)NHSO 2 R 16,(e)-C(O)NH-CH(R 14) - 四唑基,(f)-C(O)NH-杂环,和(g)-C(O) CH(R 14)-C(O)NR 17 R 18; R 3是取代或未取代的杂环或芳基,取代或未取代的环烷基或环烯基,(Ic)和-P(W)R R3是R3。 R4是氢,低级烷基,卤代烷基,卤素,芳基,芳基烷基,杂环或(杂环)烷基; (a)-L4-N(R5)-L5-,(b)-L4-O-L5-,(c)-L4-S(O)n-L5-,(d) -L4-L6-C(W)-N(R5)-L5-,(e)-L4-L6-S(O)mN(R5)-L5-,(f)-L4-N(R5)-C (W)-L7-L5-,(g)-L4-N(R5)-S(O)p -L7-L5-,(h)任选取代的亚烷基,(i)任选取代的亚烯基,(j) 亚烷基,(k)共价键,(1)(Id)和(m)(Ie)是蛋白质异戊二烯基转移酶的抑制剂。 还公开了蛋白质异戊二烯转移酶抑制组合物和抑制蛋白质异戊二烯转移酶的方法。
Abstract:
A process and pharmaceutical compositions for treating several diseases and conditions which are normally treatable with retinoid-like compounds are disclosed where the compounds used for the treatment are substantially non-teratogenic and not irritant to the skin. The process is useful for treating female mammals, including humans, who are pregnant or in the child bearing age. An important partial structural feature of the compounds which provides the non-teratogenic effect and lack of irritation of skin is shown by the formula where the partially drawn ring signifies an aromatic ring which may be carbocyclic or heteroaromatic, 6-membered or 5-membered, and may be condensed with another ring. R1 is lower alkyl, Cl, Br, or I, R2 is H, lower alkyl, Cl, Br, or I, and R3 is lower alkyl, Cl, Br, I, or is an ether, thioether, ester, thioester, amine or substituted amine group.
Abstract:
Nitrogen-containing heterocyclic compounds of formula (II) wherein R1 and R2 which signifie an alkyl group with 1 to 15 C atoms, wherein also one or several CH2-groups can be replaced by a grouping selected on the group -O-, -S-, -CO-, -O-CO-, -O-COO-, -CO-O-, -CH=CH-, -CH-halogen and -CHCN- or also by a combination of two suited groups, whereby two heteroatoms are not directly linked with one another, m is 0 or 1, Ar is 1,4-phenylen, 4,4'-bi-phenyl or 2,6-naphthylen, in each of which one or several CH-groups are replaced by an N, Z signifies -CO-O-, -O-CO-, -CH2O-, -OCH2-, CH2CH2-, -CH2CHCN-, -CHCNCH2-, -CH=CH or a single bond and A is 1, 4-cyclohexylen, unsubstituted or substituted and the 1- or 4- position, with the condition that in the case where A=unsubstituted 1,4 cyclohexil Z is -CHCNCH2- or -CH2CHCN and/or an at least one of the residues R1 and R2 at least one CH2-group is replaced by -CHCN-, such compounds being suitable for use as components of smectic liquid crystal phases.